Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,537 Million (Small Cap)
147.00
NA
0.81%
-0.13
0.79%
1.72
Revenue and Profits:
Net Sales:
83 Million
(Quarterly Results - Mar 2026)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.34%
0%
-10.34%
6 Months
-20.4%
0%
-20.4%
1 Year
19.57%
0%
19.57%
2 Years
13.72%
0%
13.72%
3 Years
-21.19%
0%
-21.19%
4 Years
-19.83%
0%
-19.83%
5 Years
-75.22%
0%
-75.22%
Tellgen Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.34%
EBIT Growth (5y)
-28.36%
EBIT to Interest (avg)
76.86
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.31
Tax Ratio
15.21%
Dividend Payout Ratio
69.90%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.26%
ROE (avg)
6.84%
Valuation key factors
Factor
Value
P/E Ratio
147
Industry P/E
Price to Book Value
2.40
EV to EBIT
127.75
EV to EBITDA
35.07
EV to Capital Employed
2.94
EV to Sales
8.37
PEG Ratio
NA
Dividend Yield
0.58%
ROCE (Latest)
2.30%
ROE (Latest)
1.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Sep'25
Change(%)
Net Sales
82.60
98.60
-16.23%
Operating Profit (PBDIT) excl Other Income
-2.00
5.10
-139.22%
Interest
0.00
0.30
-100.00%
Exceptional Items
0.70
-0.60
216.67%
Consolidate Net Profit
-6.30
2.50
-352.00%
Operating Profit Margin (Excl OI)
-24.70%
51.80%
-7.65%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -16.23% vs 17.10% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -352.00% vs 92.31% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
433.50
536.80
-19.24%
Operating Profit (PBDIT) excl Other Income
103.90
137.00
-24.16%
Interest
0.60
0.90
-33.33%
Exceptional Items
-2.50
8.20
-130.49%
Consolidate Net Profit
28.40
84.70
-66.47%
Operating Profit Margin (Excl OI)
72.70%
96.30%
-2.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.24% vs -24.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -66.47% vs -31.53% in Dec 2023
About Tellgen Corp. 
Tellgen Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






